Nova Eye Medical (EYE) Discussion, page-931

I did provide a note from the company stating that they don't see this proposal by the MACs being implemented. They note recent proposals which have been rejected, the widespread backlash against this proposal and the fact that various payers such as Cigna have recently come out in favour of procedures such as canaloplasty, recommending even more coverage!

Yes iTrack Advance has been available outside the US for about a year, though it is pretty obvious that the company was waiting for US approval before engaging in an all-out global launch. We've seen advertising efforts globally by the company explode, which makes sense as there is no point of marketing the device when the majority of doctors (about 70% of their customer base) couldn't use the device until about a couple of months ago. Given that marketing is global (ie just as many US doctors attend European conferences as do European doctors), they couldn't really isolate non-US doctors and target them alone.

The company has come out stating the expected sales trajectory as well, Tom stated clearly that the company expects "a rapid expansion of sales in the near term," though it is naturally far too early for them to give guidance on the exact numbers until the device has been in their core market (the USA) for more than a few months. At the moment, canaloplasty has far better reimbursement than stents as well

Yes it is hard to distinguish between news/noise that is sponsored by the company and news/noise that isn't. They do seem to get large audiences at their booths and events, and already have a high number of active training programs on the US. The extent of the marketing we are seeing as well is likely a good sign of explosive sales as well. It is pretty obvious for anyone who has done their research on this device that it is superior to the closest alternative Omni, which experienced rapid uptake when it was first released (200% rev growth in the first year off a similar revenue base). The company is clearly pushing this device very hard, rather than sitting around on the backsides doing nothing, which indicates to me that there is no reason why there shouldn't be a similar large expansion in sales. Also unlike the market for canaloplasty when Omni was released, the market for it now is much larger and the reimbursement situation is, currently, more favourable than before.